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Abstract The interferons are a complex group of virally
induced proteins produced by activated macrophages and
lymphocytes, which have become the mainstay of therapy
for hepatitis C infection. Sustained viral response (SVR)
rates in noncirrhotic patients vary from 40–80% with
interferon-based therapy. This, along with transplantation,
has drastically changed the course of hepatitis C virus
(HCV) infection over the last two decades. Numerous side
effects associated with interferon therapy have been
reported. These range from transient ﬂu-like symptoms to
serious effects such as cardiac arrhythmias, cardiomyopa-
thy, renal and liver failure, polyneuropathy, and myelo-
suppression. Pulmonary side effects including pneumonitis,
pulmonary ﬁbrosis, and reversible pulmonary hypertension
have been reported. Herein, we present four cases in which
irreversible pulmonary hypertension was diagnosed after
prolonged treatment with interferon alpha. In each case,
other causes of pulmonary hypertension were systemati-
cally eliminated. Pulmonary artery hypertension, which
may be irreversible, should be considered in patients being
treated with interferon alpha who present with exertional
dyspnea and do not have a readily identiﬁable inﬂamma-
tory or thromboembolic cause.
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Introduction
The interferons are a complex group of virally induced host
proteins produced by activated macrophages and lympho-
cytes. They were ﬁrst described in 1957 by Isaacs and
Lindenmann [1]. Alpha, beta, and gamma interferons have
been identiﬁed and characterized. Interferon alpha (IFNa)
has been used extensively in the treatment of hepatitis
viruses, as well as a few hematologic, nephrologic, and
dermatologic malignancies. Although the exact mechanism
of action of IFNa remains unclear, its usefulness in clinical
practice is well established. It is most commonly used to
treat chronic hepatitis C virus (HCV), either as mono-
therapy or in conjunction with ribavirin. In the past, the
dose used for this purpose has ranged from 3 to 5 million
units daily with 800–1,200 mg/day of oral ribavirin for
1 year [2]. Two pegylated IFNa preparations enabling
weekly dosing are now available and, along with ribavirin,
are the current standard of care. A biosynthetic alpha
interferon, consensus IFN (cIFN), is also available.
A sustained viral response (SVR) rate is deﬁned as
clearance of virus after 6 months following completion of
active treatment. SVR rates currently vary from 40–80% in
noncirrhotic patients depending upon the viral load,
genotype, dosage, and formulation of IFNa utilized [2].
IFNa has also been used in the treatment of chronic mye-
logenous leukemia (CML), multiple myeloma, and renal
cell carcinoma. The doses used for these nonhepatic dis-
eases, especially CML, are much higher than those used for
the treatment of HCV. Typical dosages range from 10 to 20
million units/day for 12–18 months. Nearly a third of
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logic remission and often remain disease-free for years
[3, 4].
Numerous side effects have been reported as a conse-
quence of interferon therapy. Almost all patients experi-
ence transient ﬂu-like symptoms with fever, weakness,
myalgias, headache, and tachycardia. These symptoms
typically subside over the next 24 hours and are less
prominent with treatment continuation. More serious
effects include cardiac arrhythmias, cardiomyopathy, pol-
yneuropathy, and myelosuppression, as well as liver and
renal failure. Furthermore, various autoimmune diseases
such as psoriasis, sprue, diabetes mellitus, thyroid disor-
ders, and various forms of arthritis can be exacerbated or
precipitated by IFNa therapy [5]. Pulmonary side effects
include pneumonitis, pulmonary ﬁbrosis, and a single
report of new onset pulmonary hypertension [6, 7]. Reso-
lution of these numerous untoward effects with discontin-
uation of the agent has been the rule.
Herein is reported a series of four individuals, who
developed an irreversible, progressive, and severe form of
pulmonary hypertension during treatment with IFNa for
chronic HCV. This complication has not been reported
previously and should be considered as a rare but important
adverse effect of IFNa therapy.
Case Reports
Case No. 1
GB was a 35-year-old white male who initially presented
with lower extremity edema and weakness and was found
to have end-stage liver disease due to HCV and alcohol
abuse. Over the next several months, he developed
decompensated liver disease with ascites. His past medical
history was signiﬁcant for a cholecystectomy for gall-
stones. His family history was signiﬁcant for a mother who
died of lung cancer and a father with coronary artery dis-
ease. He started drinking excessively at the age of 16 and
occasionally used other illegal drugs, including ampheta-
mines, heroin, and intranasal cocaine. He abstained from
drug and alcohol use from the time of his initial
presentation.
Physical examination was signiﬁcant for a nontender but
distended abdomen. The liver edge was 3 cm below the
costal margin and a palpable spleen tip was present.
Shifting dullness was present and pedal edema was noted
to the level of the knees. The lungs were clear bilaterally.
Cardiac examination revealed a normal rate and rhythm
with no murmurs or gallop sounds.
Initial laboratory evaluation revealed normal electro-
lytes, normal renal function, and a prothrombin time of
15.8 s (normal 10.8–12.8 s). Serum aminotransferase levels
(AST/ALT) were 226/183 IU/L, with a normal alkaline
phosphatase and total bilirubin level. The serum albumin
level was 3.3 mg/dl. A complete blood count documented a
platelet count of 89,000/mm
3. Serum tests were positive for
HCV-RNA genotype 1a infection with a viral load[
1 9 10
6 copies/mL.
An abdominal computed tomography scan revealed a
nodular cirrhotic liver with a volume of 1,600 cm
3. The
presence of prominent perigastric varices and periumbilical
collaterals consistent with portal hypertension were noted
also. Abdominal ultrasound documented the liver to have
increased echogenicity. The portal and hepatic veins as
well as the hepatic arteries were patent. A echocardiogram
documented a left ventricular ejection fraction of 60% with
normal heart valves and a normal estimated pulmonary
artery pressure (PAP).
A liver biopsy was obtained and interpreted as showing
grade 4, stage 4 disease. He was started on IFNa 3 million
units daily in May 1999 in an effort to clear his viremia
prior to transplantation. His viral load rapidly decreased
and became undetectable at 8 weeks. He underwent
orthotopic liver transplant 6 months later.
Postoperatively, he was found to have recurrent HCV
with a viral load of 8.5 9 10
5 copies/mL. He was started
on cIFN at a dose of 15 ug/day. He again responded rapidly
and was HCV polymerase chain reaction (PCR)-negative
by 8 weeks. His only complaint during the treatment period
was persistent fatigue, which was attributed to the IFNa
therapy.
After approximately 1 year of therapy, he began to
experience progressive dyspnea on exertion, fatigue, and
edema. An examination at this time revealed a resting
tachycardia; a new grade III/VI systolic ejection murmur
which increased in intensity with inspiration. He was
admitted to hospital for further evaluation and was found to
have severe pulmonary hypertension with right heart
failure.
Cardiac catheterization revealed PAP of 81/30 mmHg, a
cardiac output of 8.33 L/min, pulmonary vascular resis-
tance (PVR) of 8.26 cm H2O/L/min, and a cardiac index of
2.61 L/min/m
2. He experienced no change in his symptoms
with the use of short-acting vasodilators. A ventilation
perfusion scan was reported as having low probability for
pulmonary emboli. A diagnosis of pulmonary hypertension
of unknown etiology was made. He was classiﬁed as
NYHC III and was started on bosentan, an endothelin
receptor blocker, as well as a calcium channel blocker, a
diuretic, and digitalis.
He failed bosentan as well as treprostinil, a prostacyclin
analog, but had a minor response to epoprostenol. He
required repeated admissions for progressive cardiac
decompensation and the development of a persistent right-
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2002. The family refused an autopsy.
Case No. 2
DS was a 40-year-old female who was found to have an
HCV infection while attempting to donate blood. Her past
medical history included mild asthma, depression, a panic
disorder, and multiple orthopedic surgeries related to a
motor vehicle accident 20 years earlier, at which time she
received 3 units of packed red blood cells. Her only
medication was an inhaled bronchodilator. Social history
included a 30-pack-year smoking history with occasional
alcohol use. No intravenous drug use was reported.
A review of systems was unremarkable. Physical
examination revealed clear lungs, and cardiac examination
was with regular heart rate and no murmur or gallop.
Abdominal examination revealed normal bowel sounds, no
tenderness, and no hepatosplenomegaly. No pedal edema
was appreciated. Laboratory examination included normal
electrolytes, renal function, and liver function tests. The
patient was found to have a genotype 1b infection with a
viral load of 1.2 9 10
6 copies/mL. A liver biopsy was
obtained and interpreted as showing grade 1 stage 1 dis-
ease. Mild steatosis was noted also. An upper gastrointes-
tinal endoscopy was unremarkable. She was started on
IFNa therapy (3 million units daily) with ribavirin (800 mg
daily). The ribavirin was discontinued after 4 months
because of profound anemia (Hgb 4.5 gm/dL). She failed
to achieve viral clearance, despite being on maintenance
therapy for 32 months.
In February 2001, she reported progressive dyspnea on
exertion, edema, and weight gain. This required hospital-
ization and the IFNa therapy was discontinued. On physi-
cal examination, an elevated jugulo-venous pressure was
appreciated, the lungs were clear, and cardiac examination
revealed a grade 2/6 systolic ejection murmur at the left
lower sternal border with a prominent pulmonic second
sound that increased with inspiration. Pedal edema was
present up to her knees. Neurologic examination was
unremarkable.
An EKG showed sinus rhythm with voltage criteria for
right ventricular hypertrophy and left atrial enlargement.
Her chest X-ray was unremarkable. Pulmonary function
studies were consistent with minimal asthma. She had
unremarkable arterial blood gas on room air (pH 7.42, pO2
102, pCO2 33). A cardiac echocardiogram demonstrated
normal left ventricular ejection fraction (59%), diffusely
dilated, hypertrophied, and hypokinetic right ventricle,
severe tricuspid regurgitation, and a small pericardial
effusion without evidence of cardiac tamponade. A venti-
lation perfusion scan was interpreted as having an inter-
mediate probability of pulmonary embolism. A subsequent
pulmonary angiogram revealed no evidence of thrombo-
embolic disease. Right heart catheterization documented a
right atrial pressure of 24 mm Hg, right ventricle systolic
pressure of 67 mm Hg, right ventricle end diastolic pres-
sure of 11 mm Hg, PAP of 71/34 mm Hg with a mean
pulmonary arterial pressure of 52 mm Hg, and pulmonary
artery wedge pressure of 24 mm Hg.
Severe pulmonary hypertension with NYHC III heart
failure of uncertain etiology was diagnosed. She was star-
ted on a diuretic and a calcium channel blocker and
experienced a gradual worsening of her symptoms. Sub-
sequently, she was started on treprostinil, with stabilization
but no reversal of her pulmonary hypertension.
Case No. 3
FM was a 50-year-old male who presented initially with a
pericardial effusion in 1997. At that time, the effusion was
drained, with no speciﬁc etiology being identiﬁed, although
he was known to be HCV-positive. Subsequent workup
revealed advanced liver disease with decompensated cir-
rhosis. He underwent liver transplantation soon thereafter.
The post-transplant course was uncomplicated, except for
recurrent HCV. His past medical history was signiﬁcant for
obstructive sleep apnea, hyperthyroidism, and hypertri-
glyceridemia. Social history revealed 40-pack-year tobacco
use, which he terminated approximately 10 years earlier,
and a distant history of alcohol and cocaine use. He was
married and worked in a soft drink bottling factory. A
review of systems was noncontributory. Physical exami-
nation revealed an obese man in no distress. The lungs
were clear to auscultation bilaterally and the cardiac
examination was unremarkable. The abdomen was protu-
berant and nontender with palpable hepatosplenomegaly.
No ascites was appreciated and he had no edema.
The laboratory data was remarkable for mild renal
insufﬁciency (BUN/Cr 23 mg/dl/1.6 mg/dl) with a platelet
count of 105,000/mm
3 and a WBC count of 4.1 9 1,000
cells/mm
3. Liver function tests were normal and he was
found to have an HCV viral load of 2.5 9 10
5 copies/mL.
A liver biopsy showed stage I disease with no portal or
lobular inﬂammation and mild sinusoidal ﬁbrosis.
IFNa therapy (5 million units/day) with ribavirin
200 mg BID was initiated. After being on therapy for
10 months, he developed progressive dyspnea on exertion
with pedal edema. The patient was admitted to hospital and
the IFNa and ribavirin were discontinued. Physical exam-
ination showed him to have clear lungs, and a cardiac
examination revealed an early systolic murmur with a
prominent pulmonic second sound. The abdomen was
protuberant with easily palpable hepatomegaly and nor-
moactive bowel sounds. Mild lower extremity edema was
noted.
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which showed a signiﬁcant restrictive defect with dra-
matic reduction in diffusion capacity. Computed tomog-
raphy of the abdomen showed massive hepatomegaly
(liver volume 3,448 cc
3), splenomegaly, and ascites. A
ventilation perfusion scan was negative for thromboem-
bolic disease. An echocardiogram documented severe left
ventricular hypertrophy, enlargement of the right heart
chambers with severe tricuspid regurgitation, and an ele-
vated PAP (80 mm Hg). A diagnosis of severe pulmonary
hypertension with resultant cor pulmonale was made. The
IFN therapy was discontinued and treatment was initiated
with a diuretic and a calcium channel blocker with sta-
bilization, but there was no improvement in his pulmon-
ary hypertension.
Case No. 4
DM was a 49-year-old male who was noted to have ele-
vated serum aminotransferase levels (AST/ALT 228/136
IU/L). Workup revealed chronic HCV infection. He was in
good health and had no speciﬁc complaints. His past
medical history was unremarkable. He had no allergies and
was on no medications. Social history revealed a 40-pack-
year tobacco history and occasional use of alcohol. He
denied any intravenous drug use. Family history was neg-
ative. A review of systems was positive only for general-
ized malaise. Physical examination revealed clear lungs,
cardiac examination with no murmurs, the abdomen was
soft with a liver and a spleen palpable 3–4 ﬁnger breadths
below the costal margins. No peripheral edema was
present.
Laboratory evaluation revealed normal electrolytes
and renal function. Complete blood count showed WBC
2.8 9 1,000 cells/mm
3 and a platelet count of 80,000/
mm
3. Liver function tests documented serum aminotrans-
ferase elevations with a normal bilirubin level. HCV
genotype 1 was found with a viral load of 1.8 9 10
6
copies.
A computed tomography scan of the abdomen revealed
a cirrhotic liver with splenomegaly and evidence of portal
hypertension with recanalization of the periumbilical veins.
An upper endoscopy revealed grade II esophageal varices
with portal hypertensive gastropathy.
He was started on IFNa therapy (PEG-Intron 2 lg/kg/
week) with ribavirin (200 mg BID). Eight months after the
initiation of therapy, the patient developed progressive
dyspnea on exertion with increasing abdominal girth and
pedal edema. The IFNa and ribavirin therapy were dis-
continued. Re-evaluation at this time revealed a normal
chest X-ray. Pulmonary function tests documented a
moderate to severe decrease in diffusion capacity with a
mild reversible obstructive ventilatory defect. A cardiac
echogram documented normal left ventricular size and
function (EF 60%) and a normal right ventricular size.
Moderate tricuspid regurgitation was noted, with a mark-
edly elevated PAP of 80 mm Hg. A ventilation perfusion
scan was negative for thromboembolic disease. The patient
was diagnosed as having severe pulmonary hypertension of
unknown etiology and was treated with a diuretic and
calcium channel blocker with good results. He remains
clinically stable however, without improvement in his
pulmonary hypertension.
Discussion
In these four cases, each individual reported a new symp-
tom of respiratory insufﬁciency after prolonged therapy
with IFNa. Evaluation revealed pulmonary hypertension
which was irreversible upon discontinuation of IFNa and
with no identiﬁable etiology. There is no common variable
other than HCV and IFNa therapy among these individuals.
Three of four were noncirrhotic and 2/4 were postliver
transplant with good hepatic function and uncomplicated
postsurgical course. There was also no commonality in the
preparation of the interferon used. The dosage and duration
used were not unlike those used typically for hepatic or
hematologic disease. The dosage of cIFN used was 15 lg
daily, which was higher than the approved 9 lg/three times
per week; however, this regimen is now commonly used. It
was recently evaluated in a multicenter study, the DIRECT
trial, with validation of its safety and efﬁcacy in those who
fail standard therapy [8]. Also, it is unlikely that an inter-
action with any other medications, such as immunosup-
pressants, is contributory to this ﬁnding, but such an
association cannot be ruled out categorically.
Potential mechanisms that might explain this sequence
of events might include a pre-existing condition, IFNa-
induced pulmonary hypertension, or the acceleration of a
previously subclinical phenomenon caused by other factors
such as human herpesvirus 8 (HHV8), HCV itself, or a
previously unrecognized genetic predisposition.
The development of primary pulmonary hypertension
secondary to portal hypertension, called portopulmonary
hypertension, is a well-known entity [9]. Cirrhosis has
been reported to increase the risk of pulmonary hyper-
tension 6–20-fold [10]. This risk increases proportional to
the duration of the portal hypertension, although there is
no documented relationship to the severity of portal
hypertension, degree of hepatic failure, or fraction of
blood ﬂow shunting through the lungs [10]. It is most
often seen in patients with end-stage liver disease and is
considered as one of several rare sequelae of prolonged
portal hypertension. In the present series, only case 4 had
evidence of signiﬁcant portal hypertension prior to the
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plant prior to the time of diagnosis and patient 2 had only
mild hepatic ﬁbrosis on biopsy. In each case, other causes
of portal hypertension were pursued vigorously and sys-
tematically ruled out.
HCV is a well-known cause of cardiopulmonary
pathology. Numerous reports have linked HCV to idio-
pathic pulmonary ﬁbrosis [11, 12], pneumonitis [13], and
cardiomyopathy [14]. In this setting, pulmonary hyperten-
sion is secondary to end-stage pulmonary ﬁbrosis, which is
easily recognized with standard radiologic evaluations. In
this series, no evidence for the presence of pulmonary
ﬁbrosis was present in any of the four cases.
Thus, this series of cases suggests that an association
between pulmonary hypertension and IFNa therapy
may exist. IFNa is a powerful immunomodulator that has
a variety of effects on the lungs. Though considered
uncommon, most reported cases of adverse pulmonary
side effects related to IFNa consist of an exacerbation of
asthma [15], pleural effusion [16], an activation of sar-
coidosis [17], bronchiolitis obliterans-organizing pneu-
monia [18], and bilateral pulmonary inﬁltrates and
reversible pulmonary hypertension. Several reports have
described the phenomenon of bilateral interstitial and
alveolar inﬁltrates, which have been shown histologically
to be interstitial pneumonitis [19–21]. In contrast, there is
only one reported case of pulmonary hypertension which
was reversible, having developed in a patient receiving
IFNa for CML [7].
An association between IFNa and pulmonary hyper-
tension has been described in sheep. Hanaoka et al. found
that, 1 h after an infusion of IFNa directly into the lungs of
sheep, PAP and PVR increased signiﬁcantly and these
events coincided with elevations of thromboxane B2 in the
plasma. Furthermore, the administration of OKY-046, a
selective thromboxane synthase inhibitor, prevented these
IFNa-mediated pulmonary artery changes. This study
suggests that the thromboxane cascade, a mediator of
inﬂammation, is directly involved in the effect of IFN on
the lungs [22] and may be a mediator in the development of
pulmonary hypertension.
HCV itself has been reported to cause an occult
inﬂammatory reaction in pulmonary air spaces. Idilman
et al. [13] reported elevated levels of polymorphonuclear
neutrophils in the bronchoalveolar lavage specimens of
individuals with HCV. This suggests that a low-grade
chronic inﬂammatory reaction may be present in the
lungs of individuals with HCV infection and may con-
tribute to the alveolar and pulmonary arterial changes.
Shiomi et al. further demonstrated that IFNa exacerbates
this inﬂammatory reaction in patients with HCV. Using
gallium 67 citrate scans, they evaluated patients with
HCV before and after IFN therapy and were able to
quantitatively show increased radionucleotide uptake
post-treatment. These investigators concluded that IFNa
causes a gradual subclinical pulmonary inﬂammatory
process in a majority of the individuals treated with the
agent [23].
How then might irreversible pulmonary hypertension
occur in an individual receiving IFNa therapy? Three
possible mechanisms are worth considering.
As stated earlier, IFNa causes an acute increase in the
PVR and PAP, which results in a transient hypoxia. This
results in the local release of cytokines and arachidonic
acid metabolites that promote further smooth-muscle con-
traction, resulting in a marked transient but reversible
increase in the pulmonary vascular resistance. Over a
prolonged period of time, this phenomenon may promote
arterial smooth-muscle hypertrophy that may lead to irre-
versible pulmonary artery hypertension.
A second possibility is that HCV, like HIV, may have a
direct effect on the pulmonary endothelium mediated by
vasoactive amines, which leads to leukocyte adherence,
inﬂammatory cytokine release, and endothelial cell prolif-
eration. Additionally, it has been shown that certain vas-
culotropic viruses, such as HHV8, play a signiﬁcant
etiologic role in primary pulmonary hypertension [24].
Co-infection with such viruses may yet be another etiologic
factor in these individuals. This phenomenon may be
subclinical initially but, with the added stress of prolonged
IFNa exposure, may result in pulmonary hypertension
which may be irreversible.
Finally, a genetic predisposition such as the novel
mutation in the bone morphogenetic protein receptor type
II (BMPR2) seen in certain familial forms of primary
pulmonary hypertension [25] may have been present in
these four cases. IFNa may promote the expression of this
abnormal protein, which results in uncontrolled endothelial
cell growth and proliferation alone or in response to insults
such as HCV infection.
Regardless of the precise mechanism involved, these
four cases suggest that pulmonary artery hypertension
developing in individuals after prolonged IFN therapy may
be irreversible and should be considered in individuals
being treated with IFNa who present with exertional
dyspnea and do not have a readily identiﬁable inﬂamma-
tory or embolic cause for pulmonary artery hypertension.
Further study is needed to identify the precise pathophys-
iology of this problem and the identiﬁcation of individuals
who might be at risk for developing this life-threatening
complication of IFNa therapy.
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